Press Releases

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 18, 2024

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024

Axogen Announces Promotions on Research and Development Team

Jan 4, 2024

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 26, 2023

Axogen Announces Transition of Finance Team Leadership

Dec 6, 2023

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2023

Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Nov 7, 2023

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Oct 18, 2023